Tesofensine is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is being developed for the treatment of obesity. It is not currently approved for any use by the US Food and Drug Administration (FDA). However, it is in Phase III clinical trials for the treatment of obesity, and it is expected to be submitted for FDA approval in 2023.
Tesofensine works by blocking the reuptake of serotonin, norepinephrine, and dopamine in the brain. This increases the levels of these neurotransmitters in the brain, which can lead to a number of effects, including:
- Reduced appetite
- Increased feelings of fullness
- Increased energy expenditure
- Improved mood
In clinical trials, tesofensine has been shown to be effective in reducing body weight and body fat in people with obesity. In one study, participants who took tesofensine for 24 weeks lost an average of 12.6% of their body weight, compared to 6.5% in participants who took a placebo.
Tesofensine is also well-tolerated in most people. The most common side effects are mild and go away on their own, such as dry mouth, nausea, and insomnia.
In addition to its potential for the treatment of obesity, tesofensine is also being investigated for the treatment of other conditions, such as:
- Parkinson’s disease
- Alzheimer’s disease
- Attention deficit hyperactivity disorder (ADHD)
- Depression
However, more research is needed to confirm the safety and efficacy of tesofensine for these conditions.
Potential uses of tesofensine peptide:
- Obesity
- Parkinson’s disease
- Alzheimer’s disease
- Attention deficit hyperactivity disorder (ADHD)
- Depression
It is important to note that tesofensine is not currently approved for any use, and more research is needed to confirm its safety and efficacy for all of these conditions.
If you are considering taking tesofensine, it is important to talk to your doctor about the risks and benefits. Tesofensine may interact with other medications you are taking, and it is important to make sure that it is safe for you to take.
